[8-K] Atossa Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Atossa Therapeutics, Inc. reported on August 12, 2025 that it issued a press release announcing financial results for the quarter ended June 30, 2025 and providing a company update. The press release is attached as Exhibit 99.1 and the filing includes a cover page Interactive Data File as Exhibit 104. The Company states the information in Items 2.02 and 9.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or subject to certain Securities Act liabilities. This Current Report is signed by Heather Rees, Chief Financial Officer. No numerical financial metrics are included in the 8-K text provided here; consult Exhibit 99.1 for the detailed results and commentary.

Positive

• Timely disclosure: company publicly released a press release announcing financial results for the quarter ended June 30, 2025 and attached it as Exhibit 99.1 to the 8-K.
• Inclusion of an Interactive Data cover page (Exhibit 104) improves machine-readable accessibility of the filing.

Negative

• The 8-K text does not include any numerical financial metrics or operational details; investors must consult Exhibit 99.1 for substantive results.
• The Company states the press release shall not be deemed "filed" for Section 18 or certain Securities Act liabilities, which limits the exhibit's statutory filing protections.

Insights

Financial Analyst

TL;DR: Routine 8-K attaching a press release with Q2 2025 results; the filing itself contains no financial details, so immediate market impact is limited.

The report notifies investors that Atossa issued a press release for the quarter ended June 30, 2025 and attaches that release as Exhibit 99.1. Because the 8-K text does not include revenue, EPS, cash position, or guidance, the filing serves primarily as a pointer to the exhibit rather than a standalone disclosure of performance metrics. The company also uses standard language that the exhibit is not deemed "filed" for Section 18 purposes, which is common but reduces the filing's statutory liability profile. Investors should review Exhibit 99.1 for material numeric information.

Corporate Governance Expert

TL;DR: Properly executed Form 8-K with required exhibits and officer signature; governance procedures appear followed, but substance is in the attached press release.

The document fulfills Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits) by attaching a press release and interactive data cover page. Signature by the CFO, Heather Rees, completes the required attestation for current reports. The filing's declaration that the press release is not "filed" for certain legal purposes is routine disclosure practice. Overall, the 8-K is procedurally sound but provides limited analytic content without Exhibit 99.1.

false000148803900014880392025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Atossa Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35610	26-4753208
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
10202 5th Avenue NE, Suite 200
Seattle, Washington				98125
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 588-0256

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.18 par value		ATOS		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 12, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended June 30, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated August 12, 2025
104		Cover page Interactive Data File (embedded within the Inline XBRL document)

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Atossa Therapeutics, Inc.
Date:	August 12, 2025	By:	/s/ Heather Rees
			Heather Rees Chief Financial Officer (Principal Financial and Accounting Officer)

FAQ

What did Atossa Therapeutics (ATOS) file in this Form 8-K?

The company announced a press release dated August 12, 2025 reporting financial results for the quarter ended June 30, 2025 and attached it as Exhibit 99.1; an Interactive Data cover page is included as Exhibit 104.

Where can I find the Q2 2025 financial results for ATOS referenced in the 8-K?

The numerical results and company update are contained in the attached press release, Exhibit 99.1, which is referenced by the 8-K.

Is the press release in Exhibit 99.1 considered legally "filed" with the SEC?

No. The company explicitly states the information in Items 2.02 and 9.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or certain Securities Act liabilities.

Which exhibits were included with this ATOS 8-K?

Exhibit 99.1: Press Release dated August 12, 2025; Exhibit 104: Cover page Interactive Data File (Inline XBRL).

Who signed the Form 8-K for Atossa Therapeutics?

The filing is signed by Heather Rees, Chief Financial Officer (Principal Financial and Accounting Officer).